ALX Oncology Holdings Inc. (NASDAQ:ALXO) Holdings Raised by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 476.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,046 shares of the company’s stock after purchasing an additional 195,112 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.45% of ALX Oncology worth $394,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ALXO. Barclays PLC raised its stake in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after acquiring an additional 42,185 shares during the period. Sei Investments Co. acquired a new position in ALX Oncology during the 4th quarter valued at approximately $102,000. Los Angeles Capital Management LLC increased its position in ALX Oncology by 16.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 301,419 shares of the company’s stock worth $503,000 after buying an additional 43,640 shares during the period. JSF Financial LLC bought a new stake in ALX Oncology in the fourth quarter valued at $29,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of ALX Oncology by 12.0% during the fourth quarter. Bank of New York Mellon Corp now owns 90,003 shares of the company’s stock valued at $150,000 after acquiring an additional 9,623 shares during the period. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Stock Down 4.5 %

ALXO opened at $0.52 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The company has a market capitalization of $27.54 million, a PE ratio of -0.17 and a beta of 1.20. The stock’s fifty day moving average is $0.71 and its 200-day moving average is $1.22. ALX Oncology Holdings Inc. has a one year low of $0.46 and a one year high of $17.83.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. UBS Group reduced their price objective on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research report on Monday, January 27th. Stifel Nicolaus lowered their target price on ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of ALX Oncology in a research note on Friday, March 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and a consensus price target of $4.14.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.